Long-term outcomes of hospitalized SARS-CoV-2/COVID-19 patients with and without neurological involvement: 3-year follow-up assessment

Background and Objectives: Acute neurological manifestations are a common complication of acute COVID-19 disease. This study investigated the 3-year outcomes of patients with and without significant neurological manifestations during initial COVID-19 hospitalization. Methods: Patients infected by SARS-CoV-2 between March 1 and April 16, 2020 and hospitalized in the Montefiore Health System in the Bronx, an epicenter of the early pandemic, were included. Follow-up data was captured up to January 23, 2023 (3 years post COVID-19). This cohort consisted of 414 COVID-19 patients with significant neurological manifestations and 1199 propensity-matched COVID-19 patients without neurological manifestations. Primary outcomes were mortality, stroke, heart attack, major adverse cardiovascular events (MACE), reinfection, and hospital readmission post-discharge. Secondary outcomes were clinical neuroimaging findings (hemorrhage, active stroke, prior stroke, mass effect, and microhemorrhage, white-matter changes, microvascular disease, and volume loss). Predictive models were used to identify risk factors of mortality post-discharge. Results: More patients in the neurological cohort were discharged to acute rehabilitation (10.54% vs 3.68%, p<0.0001), skilled nursing facilities (30.67% vs 20.78%, p=0.0002) and fewer to home (55.27% vs 70.21%, p<0.0001) compared to the matched controls. Incidence of readmission for any medical reason (65.70% vs 60.72%, p=0.036), stroke (6.28% vs 2.34%, p<0.0001), and MACE (20.53% vs 16.51%, p=0.032) was higher in the neurological cohort post-discharge. Neurological patients were more likely to die post-discharge (58 (14.01%) vs 94 (7.84%), p=0.0001) compared to controls (HR=2.346, 95% CI=(1.586, 3.470), p<0.0001). The major causes of death post-discharge were heart disease (14.47%), sepsis (13.82%), influenza and pneumonia (11.18%), COVID-19 (8.55%) and acute respiratory distress syndrome (7.89%). Factors associated with mortality after leaving the hospital were belonging to the neurological cohort (OR=1.802 (1.237, 2.608), p=0.002), discharge disposition (OR=1.508, 95% CI=(1.276, 1.775), p<0.0001), congestive heart failure (OR=2.281 (1.429, 3.593), p=0.0004), higher COVID-19 severity score (OR=1.177 (1.062, 1.304), p=0.002), and older age (OR=1.027 (1.010, 1.044), p=0.002). There were no group differences in gross radiological findings, except the neurological cohort showed significantly more age-adjusted brain volume loss (p<0.05) compared to controls. Discussion: COVID-19 patients with neurological manifestations have worse long-term outcomes compared to matched controls. These findings raise awareness and the need for closer monitoring and timely interventions for COVID-19 patients with neurological manifestations.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint 215 comparison due to the exploratory nature of the study.

217 Standard Protocol Approvals, Registrations, and Patient Consents
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2023.  Figure 1 shows the discharge dispositions of the neurological and control cohorts stratified by 232 COVID-19 severity score. Patients with high severity scores were less likely to be discharged home and 233 more likely to be discharged to a SNF or hospice in both groups. However, there were relatively more 234 patients disposed to SNF and relatively fewer patients disposed to home in the neurological cohort 235 compared to the control cohort.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 29, 2023. 244 neurological cohort were discharged to home (55.27% vs 70.21%, p<0.0001) compared to the control 245 cohort. With respect to laboratory data, there were few group differences between those at admission and 246 at follow-up, as well as between groups (Supplemental Table 1). Some laboratory data at admission 247 were worse than those at follow-up and laboratory data of the neurological cohort was worse than those of 248 the control cohort.

249
Incidence of readmission (65.70% vs 60.72%, p=0.036), stroke (6.28% vs 2.34%, p<0.0001), and 250 MACE (20.53% vs 16.51%, p=0.032) were significantly higher in the neurological cohort than the control 251 cohort. There were however no significant group differences in heart attack and reinfection after 252 discharge (all p>0.05). Mortality rates were also higher in the neurological cohort compared to the control 253 cohort at 0.5 years (7.73% vs 3.67%, p=0.0004), 1 year (9.18% vs 4.92%, p=0.0009), and 3 years 254 (14.01% vs 7.84%, p=0.0001). Kaplan-Meier survival analysis (Figure 2) Figure 1A shows the distribution of COVID-19 severity scores in each cohort, 260 confirming proper propensity matching by severity score among survivors after COVID-19 261 hospitalization discharge. Primary outcomes were analyzed with respect to COVID-19 severity score for 262 survivors and non-survivors post discharge (Figure 1B-F). Readmission for any medical reasons were 263 similar among all severity scores for both cohorts. Incidence of stroke was high for all severity scores in 264 the neurological cohort but was generally lower for matching scores in the control cohort. Incidence of 265 heart attack also appeared to be trending upwards as severity score increased for both cohorts. The 266 percent of patients who had MACE was distributed over a range of scores for both cohorts, with a higher 267 COVID-19 severity scores showing a slightly higher percentage of patients with MACE at follow-up.
268 Non-survivors at follow-up had higher COVID-19 severity score compared to survivors.

269
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint Table 4A summarizes the pre-, intra-, and post-COVID-19 neuroradiological findings. The 296 numbers of pre-, intra-, and post-COVID-19 patients with imaging studies varied. Of those with imaging, 297 about 20% were MRI and 80% were CT. For qualitative assessment, 30-40% of patients had prior strokes 298 for all three time points, whereas the presence of hemorrhage, active stroke and/or mass effect were 299 relatively low (0-10% with most around 5%). There were, however, no group differences in these 300 qualitative findings for all three time points (p>0.05).

317
This study investigated the 3-year outcomes of hospitalized COVID-19 patients with and without 318 major neurological issues. The major findings are: i) COVID-19 patients with significant neurological 319 issues that warranted neuroimaging were more likely to be discharged to acute rehabilitation and skilled 320 nursing facilities compared to matched controls, ii) the neurological cohort had higher mortality rates . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint 321 after discharge (HR=2.346, p<0.0001) compared to controls, iii) the incidence of readmission, stroke, and 322 MACE, but not heart attack or reinfection, were higher in the neurological cohort at 3 years follow-up, iv) 323 the primary causes of death after discharge for both cohorts were heart failure, sepsis, influenza and 324 pneumonia, COVID-19 and ARDS, v) patients who died post-discharge were significantly older, more 325 likely to be male, had higher COVID-19 severity score, and those were sent to skilled nursing facilities at 326 discharge compared to survivors, vi) there were no group differences in gross radiological findings with 327 respect to hemorrhage and stroke, except the neurological cohort showed significantly more age-328 appropriate volume loss than the control cohort.

329
330 Disposition: Approximately half of the neurological patients and one-thirds of the control patients were 331 discharged to SNF, acute rehabilitation, or hospice. These findings indicated that many COVID-19 332 patients were not functionally independent after discharge(22-24), especially those in the neurological 333 cohort. Few studies today have reported home, SNF, and acute rehabilitation discharge rates after 334 COVID-19 hospitalization(22-26). These findings suggest that patients in the neurological cohort likely 335 needed more follow-up medical care at discharge. 336 337 Primary outcomes: The majority (60-65%) of all neurological and control patients were readmitted to our 338 health system for medical reasons over 3 years. This is not surprising for our cohort due to advanced age 339 and high prevalence of comorbidities, although it is higher than reported in some studies(27-30). 340 Readmission could be due to age-related illness or medical conditions exacerbated by COVID-19. The 341 neurological cohort had a higher readmission rate than the control cohort, suggesting that a higher burden 342 of disease during COVID-19 hospitalization may be associated with a higher probability of re-343 hospitalization.

344
The incidence of stroke was 2-6% and of heart attack was 4-5% in both groups. The incidence of 345 MACE after discharge (16-20%) was higher than other reported previously in COVID-19 who did not 346 have neurological issues(18). A few studies have suggested COVID-19 exerts long-term cardiovascular . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2023.

353
Of those who died post-discharge, more than half died within the first 0.5 years in both groups, 354 suggesting that most of these deaths were likely COVID-19 related. The cumulative mortality rates of the 355 neurological and control cohorts at 3 years post-discharge were 14% and 8%, respectively. The marked 356 mortality rate differences between groups are highlighted by the Kaplan-Meier analysis. Those who died 357 at follow-up in both groups were 8 years older and more likely to be male as compared to survivors.
358 Elderly patients may be more prone to exhibiting early neurologic symptoms because of limited cognitive 359 reserve. This is widely seen in other medical conditions such as urosepsis. Patients presenting with early 360 neurologic compromise could be a harbinger of susceptibility for higher mortality across other disease 361 states. Male gender has been previously reported to have worse acute in-hospital outcomes, including 362 higher rate of multi-organ injury, critical care illness, and in-hospital mortality(37-40). Here we reported 363 male gender also had worse long-term outcomes post COVID-19 discharge. 364 Logistic regression model identified discharge disposition to be the top risk factor for post-365 discharge mortality, followed by CHF, COVID-19 severity score, belonging to the neurological cohort, 366 and age. CHF was the only comorbidity that was significantly associated with post-discharge mortality.
367 Patients who had more severe COVID-19 disease were also more likely to die post discharge. Belonging 368 to the neurological cohort was also independent risk factor for post-discharge mortality. It is not 369 surprising that advanced age is associated with higher post-discharge mortality, but advanced age ranked 370 lower than other variables mentioned above. Note that OR for male gender was trending significance and 371 we predicted that large sample sizes could result in significant findings. Taken together, these findings . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint 372 underscore the independent risk factors that contributed to post discharge mortality and notably belonging 373 to the neurological cohort is a significant independent risk factor. 374 375 Cause of Death: The causes of death were similar between neurological and control cohorts, consistent 376 with findings using logistic regression in which belonging to neurological cohort was an important but not 377 the most important associative variable of post COVID-19 discharge mortality. The primary known 378 causes of death in both the neurological and control cohorts were heart disease, sepsis, influenza and 379 pneumonia, COVID-19, and ARDS. Sepsis, pneumonia, and ARDS might be related to or be triggered by 380 COVID-19, although they could also be a result of other medical events. It is possible that COVID-19 as 381 a cause of death was underestimated as a result of imprecise categorization in the death certificates. Note 382 that about one-third of the causes of death were specified as unknown on the death certificates. It is 383 possible that some patients died of senescence and no primary cause of death was noted. 384 385 Imaging Findings: Age of patient was taken into consideration when assessing neuroradiological 386 findings. Imaging findings of control and neurological patients displayed differential profiles of 387 abnormalities that were consistent with age and comorbidities in this population. The differences in 388 radiological findings between baseline and follow-up showed age-related effects. However, there were 389 generally no group differences in qualitative nor score-based findings, except that the neurological cohort 390 showing higher volume loss post-COVID-19 compared to controls.

391
Several case reports and few cohort studies have identified reduction in grey-matter thickness, 392 ischemic stroke, decrease in global brain size, cerebral microstructural changes, and persistent WM 393 changes associated with COVID-19(41-47). There is likely some reporting bias in case or case-series 394 studies as positive clinical imaging findings associated with COVID-19 are more likely to be reported. 395 Most of these studies do not compare findings to baseline, which makes it difficult to discern whether 396 imaging abnormalities were pre-existing or a consequence of COVID-19 disease. None of these studies 397 employ a scoring system to accentuate the degree of abnormality. Our study is novel because of its large . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint 398 and diverse patient population, long follow-up times, the use of a scoring system, and comparison 399 between baseline and follow-up studies to 3 years post-discharge. It is possible that COVID-19 related 400 changes in the brain anatomy and structure could take time to manifest, and we predict that some COVID-401 19 patients will likely experience accelerated aging and high incidence of age-related disorders. Brain

436
Although the attrition is low (10%), patients who did not return to our health system could not be 437 studied. While it is possible that returning patients were more likely to have more severe COVID-19, our 438 patient data consisted of those who returned for any medical reasons, including regular checkups. On the 439 other hand, those who did not return might have expired. Our current study was not powered to address . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

613
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

618
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint 619 Table 3. (A) Demographics and comorbidities of patients who died versus survived after discharge in the 620 neurological and control cohorts. Patients lost to follow up were excluded. Mean±SD or n (%). * p<0.05, 621 ** p<0.01, *** p<0.001 between survivors or non-survivors in the neurological and control cohorts. ^ 622 p<0.05, ^^ p<0.01, ^^^ p<0.001 between survivors and non-survivors in the same cohort. (B) Odds ratios 623 of mortality post discharge.

637
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint 638 Figure 1. Percent of patients in the neurological and control cohorts discharged to home, acute 639 rehabilitation, skilled nursing facility (SNF), hospice, and others for different COVID-19 severity score. 640 641 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

646
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint 654 Supplemental Figure 1. (A) Distribution of COVID-19 severity score in the neurological and control 655 cohorts (survivors after COVID-19 hospitalization discharge). Percent of patients in the neurological and 656 control cohorts who (B) were readmitted, (C) had stroke, (D) had heart attack, (E) had MACE, and (F) 657 died after discharge from COVID-19 hospitalization.

658
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 29, 2023. ; https://doi.org/10.1101/2023.06.26.23291883 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.